Tonix Pharmaceitocals shares are trading higher after the company announced data on the potential mpox vaccine TNX-801 in "Using Synthetic Biology To Battle Mpox" talk at immunology symposium at the University of Alberta
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals shares rose following the announcement of data on their potential mpox vaccine, TNX-801, presented at an immunology symposium.
September 09, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' stock price increased after the company presented promising data on its potential mpox vaccine, TNX-801, at a symposium.
The announcement of new data on TNX-801, a potential mpox vaccine, is a significant development for Tonix Pharmaceuticals, likely boosting investor confidence and driving the stock price up. The presentation at a reputable symposium adds credibility to the data.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100